Audio

Erich B. Ringelstein, MD, Discusses the Difficulties in Developing Neuroprotective Drugs

Neurology Reviews. 2012 March;20(3):15

 

To read the accompanying article, please click here.

Recommended Reading

You Read It Here First: Tenecteplase for Stroke
MDedge Neurology
Vorapaxar Cuts Cardiovascular Events but Boosts Bleeding
MDedge Neurology
Telestroke Triage Comes of Age
MDedge Neurology
Elderly Stroke Patients Have High Atrial Fibrillation Prevalence
MDedge Neurology
FDA Panel Questions Intracranial Stent Approval
MDedge Neurology
Warfarin Versus Aspirin for Stroke Prevention
MDedge Neurology
Can Whole Exome Sequencing Identify a Genetic Risk for Intracranial Aneurysm?
MDedge Neurology
Experimental Drug Does Not Reduce Stroke-Related Disability
MDedge Neurology
Atrial Fibrillation Is Prevalent Among Patients With Cryptogenic Cerebral Ischemia
MDedge Neurology
Literature Monitor
MDedge Neurology